Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Canaccord Genuity 31st Annual Growth Conference
WALTHAM, Mass., Aug 05, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that its presentation at the Canaccord
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Provides Corporate Update and Fiscal Year 2012 Guidance
Company's Strong Cash Position Supports Aggressive Development of Wholly Owned Product Candidates As Partner Compounds Advance Multiple Compounds Expected to Advance to Next Stage within 12 Months
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2011 Financial Results
WALTHAM, Mass., Jul 28, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 4:30 p.m.
View HTML